Real-World Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn’s Disease
In a real-world setting, clinical response, clinical remission, SAEs, and HCRU were similar in patients treated with vedolizumab and ustekinumab during 36 treatment months. Treatment persistence was higher with ustekinumab. Mucosal healing was higher with vedolizumab (see Supplemental Digital Content 1 for visual summary, http://links.lww.com/JCG/B336).
Authors
- Pravin Kamble (ORCID: https://orcid.org/0000-0003-0395-4494)
- Lauren Gianchetti (ORCID: https://orcid.org/0000-0002-9665-6076)
- Marielle Bassel
- B Christensen
- Shashi Adsul
- Brian Bressler
- Marc Ferrante
- Neil R. Brett
Institutions
- The Royal Melbourne Hospital (AU)
- University of British Columbia (CA)
- The University of Melbourne (AU)
- University of Zurich (CH)
- Thermo Fisher Scientific (Canada) (CA)
- University Hospital of Zurich (CH)
- Takeda (United States) (US)
- Thermo Fisher Scientific (United States) (US)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/mcg.0000000000002350
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00